Ascent Group LLC Trims Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Ascent Group LLC reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 470 shares of the biopharmaceutical company’s stock after selling 35 shares during the period. Ascent Group LLC’s holdings in Regeneron Pharmaceuticals were worth $494,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in REGN. Park Avenue Securities LLC increased its stake in Regeneron Pharmaceuticals by 5.0% during the 2nd quarter. Park Avenue Securities LLC now owns 1,755 shares of the biopharmaceutical company’s stock worth $1,845,000 after buying an additional 84 shares during the period. CWM LLC increased its stake in Regeneron Pharmaceuticals by 2.2% during the 2nd quarter. CWM LLC now owns 2,247 shares of the biopharmaceutical company’s stock worth $2,361,000 after buying an additional 49 shares during the period. U.S. Capital Wealth Advisors LLC increased its stake in Regeneron Pharmaceuticals by 3.2% during the 2nd quarter. U.S. Capital Wealth Advisors LLC now owns 2,175 shares of the biopharmaceutical company’s stock worth $2,286,000 after buying an additional 67 shares during the period. GuoLine Advisory Pte Ltd increased its stake in Regeneron Pharmaceuticals by 23.8% during the 2nd quarter. GuoLine Advisory Pte Ltd now owns 32,060 shares of the biopharmaceutical company’s stock worth $33,696,000 after buying an additional 6,160 shares during the period. Finally, Gilman Hill Asset Management LLC increased its stake in Regeneron Pharmaceuticals by 4.7% during the 2nd quarter. Gilman Hill Asset Management LLC now owns 5,123 shares of the biopharmaceutical company’s stock worth $5,384,000 after buying an additional 231 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $754.26 on Thursday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The company has a 50-day simple moving average of $887.58 and a 200-day simple moving average of $1,014.72. Regeneron Pharmaceuticals, Inc. has a 52-week low of $735.95 and a 52-week high of $1,211.20. The company has a market capitalization of $82.89 billion, a PE ratio of 18.67, a P/E/G ratio of 2.94 and a beta of 0.08.

Wall Street Analyst Weigh In

REGN has been the subject of several analyst reports. Cantor Fitzgerald reiterated a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Wells Fargo & Company lowered their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, October 22nd. BMO Capital Markets lowered their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price target for the company. Finally, Leerink Partners reiterated a “market perform” rating and set a $1,077.00 price target (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,107.29.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.